| Michael Vertin Hall, OD | |
|
Brian D. Allgood Army Community Hospital (bdaach), Unit #15245, Apo, AP 96271 | |
| (315) 737-1464 | |
| Not Available |
| Full Name | Michael Vertin Hall |
|---|---|
| Gender | Male |
| Speciality | Optometrist |
| Location | Brian D. Allgood Army Community Hospital (bdaach), Apo, Armed Forces Pacific |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497237697 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPT.0003423 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael Vertin Hall, OD Brian D. Allgood Army Community Hospital (bdaach), Unit# 15245; Bldg 3031, Apo, AP 96271 Ph: (315) 737-1464 | Michael Vertin Hall, OD Brian D. Allgood Army Community Hospital (bdaach), Unit #15245, Apo, AP 96271 Ph: (315) 737-1464 |
News Archive
PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.
A combination of two types of blood pressure-lowering drugs, an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) with agalsidase-beta (Fabrazyme, Genzyme Corporation, Cambridge, MA) is the first treatment shown to stop progressive loss of kidney function in patients with severe kidney involvement due to the rare genetic disorder Fabry disease, reports a study in the September Journal of the American Society of Nephrology.
InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the LipiScan IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound and near-infrared spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events.
A combination of two drugs may alleviate radiation sickness in people who have been exposed to high levels of radiation, even when the therapy is given a day after the exposure occurred, according to a study led by scientists from Dana-Farber Cancer Institute and Children's Hospital Boston.
› Verified 6 days ago
Dr. Justin E Sandholm, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 35 Hcos/cc, Psc 76 Unit 5024, Apo, AP 96319 Phone: 071-677-6269 | |
Lewis Bruneel, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 18th Medical Group, Apo, AP 96368 Phone: 544-630-2947 | |
Melanie A Riley Peters, OD Optometrist Medicare: Medicare Enrolled Practice Location: 121 Brian Allgood Hospital, Unit 15244, Apo, AP 96205 Phone: 315-737-1470 | |
Timothy Soh, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: Brian D. Allgood Army Community Hospital, Dha, Apo, AP 96271 Phone: 315-737-1449 | |
Dr. Nicole Elizabeth Nowling, OD Optometrist Medicare: Medicare Enrolled Practice Location: 51st Medical Group, Unit 2060, Apo, AP 96278 Phone: 315-784-2151 | |
Nicholas Jon Hardgrave, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 36th Medical Group-andersen Afb Clinic/optometry, Unit 14010, Apo, AP 96543 Phone: 671-366-6749 | |
Dr. Min Kyung Kim, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: Unit 15245, Apo, AP 96271 Phone: 315-737-1219 |